Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03586414 · ClinicalTrials.gov registry record · NA
MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women
A NA study of Diastolic Dysfunction, sponsored by University of Colorado, Denver.
- Active
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT03586414: Active NA study of Diastolic Dysfunction, sponsored by University of Colorado, Denver.
NCT03586414 is a NA study of Diastolic Dysfunction that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 31 participants, below the 583-participant average among 4 other Diastolic Dysfunction trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03586414, a NA study of Diastolic Dysfunction, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
In this pilot study, the investigators will determine whether supplementation with a mitochondrial-targeted antioxidant (Mitoquinone (MitoQ)) improves mitochondrial function, left ventricular diastolic and vascular function.
Primary Outcome
Echocardiographic measurements of LV function (and structure) will be assessed; primary outcomes include peak early (E) to late (A) mitral inflow velocity ratio and E to peak early (e') mitral annular velocity ratio.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT MITOQUINOL MESYLATE then placebo
- DIETARY_SUPPLEMENT Placebo, then MITOQUINOL MESYLATE
Study Locations (1)
Colorado
- University of Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2030-08 |
| Phase | NA |
What the registry record for NCT03586414 still lists
NCT03586414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 583-participant average among 4 other Diastolic Dysfunction trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Diastolic Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which MITOQUINOL MESYLATE then placebo is the first listed.
NCT03586414 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03586414 about?
NCT03586414 is a clinical study titled "MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women". In this pilot study, the investigators will determine whether supplementation with a mitochondrial-targeted antioxidant (Mitoquinone (MitoQ)) improves mitochondrial function, left ventricular diastolic and vascular function.
What is the current status of trial NCT03586414?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 31 participants. The study started on 2021-08-01. Estimated completion is 2030-08.
What conditions does trial NCT03586414 study?
This clinical trial studies the following conditions: Diastolic Dysfunction.
What interventions are being tested in trial NCT03586414?
The interventions under investigation include: MITOQUINOL MESYLATE then placebo (DIETARY_SUPPLEMENT), Placebo, then MITOQUINOL MESYLATE (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03586414?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03586414 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diastolic Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES
RECRUITING · Phase 1
-
AI in Outpatient Practice for Diagnosing Aortic Stenosis and Diastolic Dysfunction
RECRUITING
-
Targeting Inflammation to Treat Cardiovascular Aging
COMPLETED · Phase 2
-
PDD in Type 2 Diabetes w/wo Diastolic Dysfunction
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI